BACKGROUND AND PURPOSE: The non-nucleoside analogue reverse transcriptase inhibitor efavirenz is associated with hepatic toxicity and metabolic disturbances. Although the mechanisms involved are not clear, recent evidence has pinpointed a specific mitochondrial action of efavirenz accompanied by the induction of an endoplasmic reticulum (ER) stress/unfolded protein response in human hepatic cells. The aim of this study was to further investigate the involvement of this organelle by evaluating efavirenz's effects in cells lacking functional mitochondria (rho°) and comparing them with those of the typical mitotoxic agent rotenone, a standard complex I inhibitor, and the ER stress inducer thapsigargin. EXPERIMENTAL APPROACH: Hep3B rho(+) and rho° cells were treated with clinically relevant concentrations of efavirenz, then mitochondrial function and cytotoxicity were studied using standard cell biology techniques. KEY RESULTS: Efavirenz-treated rho° cells exhibited a substantial reduction in parameters indicative of mitochondrial interference, such as increased superoxide production, mitochondrial mass/morphology alterations and enhanced expression of LONP, a highly conserved mitochondrial protease. In line with these results, the cytotoxic effect (cell number, chromatin condensation, cell cycle alterations and induction of apoptosis) of efavirenz was less pronounced in Hep3B respiration-depleted cells than in wild-type cells. The effect of efavirenz was both similar and different from those of two distinct mitochondrial stressors, thapsigargin and rotenone. CONCLUSIONS AND IMPLICATIONS: Cells lacking normal mitochondria (rho°) are less vulnerable to efavirenz. Our results provide further evidence that the hepatic damage induced by efavirenz involves acute interference with mitochondria and extend our knowledge of the response of mitochondria/ER to a stress stimulus.
BACKGROUND AND PURPOSE: The non-nucleoside analogue reverse transcriptase inhibitor efavirenz is associated with hepatic toxicity and metabolic disturbances. Although the mechanisms involved are not clear, recent evidence has pinpointed a specific mitochondrial action of efavirenz accompanied by the induction of an endoplasmic reticulum (ER) stress/unfolded protein response in human hepatic cells. The aim of this study was to further investigate the involvement of this organelle by evaluating efavirenz's effects in cells lacking functional mitochondria (rho°) and comparing them with those of the typical mitotoxic agent rotenone, a standard complex I inhibitor, and the ER stress inducer thapsigargin. EXPERIMENTAL APPROACH: Hep3B rho(+) and rho° cells were treated with clinically relevant concentrations of efavirenz, then mitochondrial function and cytotoxicity were studied using standard cell biology techniques. KEY RESULTS:Efavirenz-treated rho° cells exhibited a substantial reduction in parameters indicative of mitochondrial interference, such as increased superoxide production, mitochondrial mass/morphology alterations and enhanced expression of LONP, a highly conserved mitochondrial protease. In line with these results, the cytotoxic effect (cell number, chromatin condensation, cell cycle alterations and induction of apoptosis) of efavirenz was less pronounced in Hep3B respiration-depleted cells than in wild-type cells. The effect of efavirenz was both similar and different from those of two distinct mitochondrial stressors, thapsigargin and rotenone. CONCLUSIONS AND IMPLICATIONS: Cells lacking normal mitochondria (rho°) are less vulnerable to efavirenz. Our results provide further evidence that the hepatic damage induced by efavirenz involves acute interference with mitochondria and extend our knowledge of the response of mitochondria/ER to a stress stimulus.
Authors: Nadezda Apostolova; Leysa J Gomez-Sucerquia; Anna Gortat; Ana Blas-Garcia; Juan V Esplugues Journal: Hepatology Date: 2011-08-02 Impact factor: 17.425
Authors: Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues Journal: Hepatology Date: 2010-07 Impact factor: 17.425
Authors: M A Loko; F Bani-Sadr; M Winnock; K Lacombe; P Carrieri; D Neau; P Morlat; L Serfaty; F Dabis; D Salmon Journal: J Viral Hepat Date: 2011-01-11 Impact factor: 3.728
Authors: Jose J G Marin; Alicia Hernandez; Isabel E Revuelta; Ester Gonzalez-Sanchez; Jose M Gonzalez-Buitrago; Maria J Perez Journal: Free Radic Biol Med Date: 2013-04-16 Impact factor: 7.376
Authors: Fernando Alegre; Ángela B Moragrega; Miriam Polo; Alberto Marti-Rodrigo; Juan V Esplugues; Ana Blas-Garcia; Nadezda Apostolova Journal: Br J Pharmacol Date: 2018-01-06 Impact factor: 8.739
Authors: Miriam Polo; Fernando Alegre; Angela B Moragrega; Lara Gibellini; Alberto Marti-Rodrigo; Ana Blas-Garcia; Juan V Esplugues; Nadezda Apostolova Journal: Br J Pharmacol Date: 2017-11-07 Impact factor: 8.739
Authors: Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz Journal: Acta Pharm Sin B Date: 2021-11-18 Impact factor: 11.413
Authors: Sumanth Karamchand; Rory Leisegang; Michael Schomaker; Gary Maartens; Lourens Walters; Michael Hislop; Joel A Dave; Naomi S Levitt; Karen Cohen Journal: Medicine (Baltimore) Date: 2016-03 Impact factor: 1.889